Perioperative pharmacotherapy in patients with left ventricular assist devices

Drugs and Aging

Volumn 21, Issue 15, 2004, Pages 993-1012

  Dang, Nicholas C ^a   Naka, Yoshifumi ^a  

^a Columbia Univ Coll of Phys/Surgs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APROTININ; CEFAZOLIN; CLENBUTEROL; COTRIMOXAZOLE; DIPYRIDAMOLE; DOBUTAMINE; DOPAMINE; FLUCONAZOLE; GENTAMICIN; HEPARIN; INOTROPIC AGENT; INSTAT MCH; MICROCRYSTALLINE COLLAGEN; MILRINONE; NESIRITIDE; NITRIC OXIDE; NORADRENALIN; PHYTOMENADIONE; PROSTAGLANDIN E1; PSEUDOMONIC ACID; RECOMBINANT HIRUDIN; RIFAMPICIN; UNINDEXED DRUG; VANCOMYCIN; VASOPRESSIN; WARFARIN;

ANAPHYLAXIS; ANTIBIOTIC PROPHYLAXIS; ANTICOAGULANT THERAPY; ANTIOXIDANT ACTIVITY; BACTERIAL INFECTION; BLEEDING; CANDIDIASIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; ENDOCARDITIS; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE; HEMOSTASIS; HUMAN; IMPLANTATION; MYCOSIS; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; POSTOPERATIVE INFECTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; THRUSH; VITAMIN INTAKE;

AGED; ANTI-INFECTIVE AGENTS; ANTICOAGULANTS; CARDIOVASCULAR AGENTS; DRUG THERAPY; HEART-ASSIST DEVICES; HEMODYNAMIC PROCESSES; HUMANS; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE CARE; VENTRICULAR FUNCTION, LEFT;

EID: 11344252288     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421150-00003     Document Type: Review

References (143)

1. American Heart Association. Heart disease and stroke statistics [online]. Available from URL: http://www.americanheart.org/downloadable/heart/ 10590179711482003HDSStatsBook-REV7-03.pdf [Accessed 2003 Oct 20]
2. Stevenson LW. When is heart failure a surgical disease? In: Rose EA, Stevenson LW, editors. Management of end-stage heart disease. 1st ed. Philadelphia (PA): Lipincott-Raven, 1998: 129-46
3. Goldstein DJ, Rose EA. Cadiac allotransplantation. In: Rose EA, Stevenson LW, editors. Management of end-stage heart disease. 1st ed. Philadelphia (PA): Lipincott-Raven, 1998: 177-85
4. Mancini DM, Beniaminovitz A, Levin H, et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation 1998 Dec 1; 98 (22): 2383-9
5. Hetzer R, Muller J, Weng Y, et al. Cardiac recovery in dilated cardiomyopathy by unloading with a left ventricular assist device. Ann Thorac Surg 1999 Aug; 68 (2): 742-9
6. Hetzer R, Muller JH, Weng YO, et al. Midterm follow-up of patients who underwent removal of a left ventricular assist device after cardiac recovery from end-stage dilated cardiomyopathy. J Thorac Cardiovasc Surg 2000 Nov; 120 (5): 843-53
7. Hetzer R, Muller JH, Weng Y, et al. Bridging-to-recovery. Ann Thorac Surg 2001 Mar; 71 (3 Suppl.): S109-15
8. Rose EA, Gelijns AC, Moskowitz AJ, et al., Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001 Nov 15; 345 (20): 1435-43
9. Kellum JA, Pinsky MR. Use of vasopressor agents in critically ill patients. Curr Opin Crit Care 2002 Jun; 8 (3): 236-41
10. Nakajima Y, Hayashi Y, Miyashita T, et al. Anesthetic management of patients undergoing implantation of left ventricular assist system. Masui 1999 Jul; 48 (7): 767-72
11. McGhie AI, Golstein RA. Pathogenesis and management of acute heart failure and cardiogenic shock: role of inotropic therapy. Chest 1992 Nov; 102 (5 Suppl. 2): 626S-32S
12. Duke GJ, Bersten AD. Dopamine and renal salvage in the critically ill patient. Anaesth Intensive Care 1992 Aug; 20 (3): 277-87
13. Richer M, Robert S, Lebel M. Renal hemodynamics during norepinephrine and low-dose dopamine infusions in man. Crit Care Med 1996 Jul; 24 (7): 1150-6
14. Carcoana OV, Hines RL. Is renal dose dopamine protective or therapeutic? Yes. Crit Care Clin 1996 Jul; 12 (3): 677-85
15. Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000 Dec 23-30; 356 (9248): 2139-43
16. Aurora RN, Milite F, Carton G. Preventing renal failure in critically ill patients. Crit Care Med 1999 Sep; 27 (9): 2044-5
17. Day NP, Phu NH, Mai NT, et al. Effects of dopamine and epinephrine infusions on renal hemodynamics in severe malaria and severe sepsis. Crit Care Med 2000 May; 28 (5): 1353-62
18. Power DA, Duggan J, Brady HR. Renal-dose (low-dose) dopamine for the treatment of sepsis-related and other forms of acute renal failure: ineffective and probably dangerous. Clin Exp Pharmacol Physiol Suppl 1999 Apr; 26: S23-8
19. Moazemi K, Chana JS, Willard AM, et al. Intravenous vasodilator therapy in congestive heart failure. Drugs Aging 2003; 20 (7): 485-508
20. Aranda Jr JM, Schofield RS, Pauly DF, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J 2003 Feb; 145 (2): 324-9
21. Alousi AA, Canter JM, Montenarp MJ, et al. Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J Cardiovasc Pharmacol 1983 Sep-Oct; 5 (5): 792-803
22. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure: mechanisms of action and recent clinical developments. 2. N Engl J Med 1986 Feb 6; 314 (6): 349-58
23. Kihara S, Kawai A, Fukuda T, et al. Effects of milrinone for right ventricular failure after left ventricular assist device implantation. Heart Vessels 2002 Jan; 16 (2): 69-71
24. Peterzen B, Granfeldt H, Lonn U, et al. Management of patients with end-stage heart disease treated with an implantable left ventricular assist device in a nontransplanting center. J Cardiothorac Vasc Anesth 2000 Aug; 14 (4): 438-43
25. Koyanagi T, Kyo S, Ouchi H, et al. Clinical experience of milrinone as a pharmacological bridge to heart transplantation. Jpn J Thorac Cardiovasc Surg 2000 Jul; 48 (7): 460-3
26. Jaggers J, Fullerton DA, Campbell DN, et al. Cardiac allograft failure: successful use of biventricular assist device. Ann Thorac Surg 1995 Nov; 60 (5): 1409-11
27. Goldstein RA, Geraci SA, Gray EL, et al. Electrophysiologic effects of milrinone in patients with congestive heart failure. Am J Cardiol 1986 Mar 1; 57 (8): 624-8
28. Moroney DA, Swartz MT, Reedy JE, et al. Importance of ventricular arrhythmias in recovery patients with ventricular assist devices. ASAIO Trans 1991 Jul-Sep; 37 (3): M516-7
29. Oz MC, Rose EA, Slater J, et al. Malignant ventricular arrhythmias are well tolerated in patients receiving long-term left ventricular assist devices. J Am Coll Cardiol 1994 Dec; 24 (7): 1688-91
30. Arai H, Swartz MT, Pennington DG, et al. Importance of ventricular arrhythmias in bridge patients with ventricular assist devices. ASAIO Trans 1991 Jul-Sep; 37 (3): M427-8
31. Forrest P. Vasopressin and shock. Anaesth Intensive Care 2001; 29: 463-72
32. Nolan JP, De Latorre FJ, Steen PA, et al. Advanced life support drugs: do they really work? Curr Opin Crit Care 2002 Jun; 8 (3): 212-8
33. Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997 Nov 4; 96 (9 Suppl.): II-286-90
34. Mavroidis D, Sun BC, Pae Jr WE. Bridge to transplantation: the Penn State experience. Ann Thorac Surg 1999 Aug; 68 (2): 684-7
35. Morales DL, Gregg D, Helman DN, et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 2000 Jan; 69 (1): 102-6
36. Helman DN, Oz MC. Developing a comprehensive mechanical support program. J Cardiac Surg 2001 May-Jun; 16 (3): 203-8
37. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel presser agent. J Thorac Cardiovasc Surg 1998 Dec; 116 (6): 973-80
38. Chen P. Vasopressin: new uses in critical care. Am J Med Sci 2002 Sep; 324 (3): 146-54
39. Landry DW, Levin HR, Gallant EM, et al. Vasopressin presser hypersensitivity in vasodilatory septic shock. Crit Care Med 1997; 25: 1279-82
40. Wagner Jr HN, Braunwald E. The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J Clin Invest 1956; 35: 1412-8
41. Edwards RM, Rizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonist. Am J Physiol 1989; 256: F274-8
42. Massion PB, Feron O, Dessy C, et al. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 2003 Sep 5; 93 (5): 388-98
43. Haddad E, Lowson SM, Johns RA, et al. Use of inhaled nitric oxide perioperatively and in intensive care patients. Anesthesiology 2000 Jun; 92 (6): 1821-5
44. Argenziano M, Choudhri AF, Moazami N, et al. Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension. Ann Thorac Surg 1998 Feb; 65 (2): 340-5
45. Salamonsen RF, Kaye D, Esmore DS. Inhalation of nitric oxide provides selective pulmonary vasodilatation, aiding mechanical cardiac assist with Thoratec left ventricular assist device. Anaesth Intensive Care 1994 Apr; 22 (2): 209-10
46. Hare JM, Shernan SK, Body SC, et al. Influence of inhaled nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance. Circulation 1997 May 6; 95 (9): 2250-3
47. Chang JC, Sawa Y, Ohtake S, et al. Hemodynamic effect of inhaled nitric oxide in dilated cardiomyopathy patients on LVAD support. ASAIO J 1997 Sep-Oct; 43 (5): M418-21
48. Wagner F, Dandel M, Gunther G, et al. Nitric oxide inhalation in the treatment of right ventricular dysfunction following left ventricular assist device implantation. Circulation 1997 Nov 4; 96 (9 Suppl.): II-291-6
49. Macdonald PS, Keogh A, Mundy J, et al. Adjunctive use of inhaled nitric oxide during implantation of a left ventricular assist device. J Heart Lung Transplant 1998 Mar; 17 (3): 312-6
50. Beck JR, Mongero LB, Kroslowitz RM, et al. Inhaled nitric oxide improves hemodynamics in patients with acute pulmonary hypertension after high-risk cardiac surgery. Perfusion 1999 Jan; 14 (1): 37-42
51. Johnson RG. Prostaglandin El and myocardial reperfusion injury. Crit Care Med 2000 Jul; 28 (7): 2649-50
52. Shorten G, Comunale ME, Johnson RG. Management of cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia using prostaglandin El and aspirin. J Cardiothorac Vase Anesth 1994; 8: 556-8
53. Pacher R, Stanek B, Hulsmann M, et al. Effect of prostaglandin El infusion in severe chronic heart failure. Prostaglandins 1997 Apr; 53 (4): 221-35
54. Kawamura T, Nara N, Kadosaki M, et al. Prostaglandin El reduces myocardial reperfusion injury by inhibiting proinflammatory cytokines production during cardiac surgery. Crit Care Med 2000 Jul; 28 (7): 2201-8
55. Fonger JD, Borkon AM, Baumgartner WA, et al. Acute right ventricular failure following heart transplantation: improvement with prostaglandin El and right ventricular assist. J Heart Transplant 1986 Jul-Aug; 5 (4): 317-21
56. Jeevanandam V, Mather P, Furukawa S, et al. Adult orthotopic heart transplantation using undersized pediatric donor hearts: technique and postoperative management. Circulation 1994 Nov; 90 (5 Pt 2): II74-7
57. Waldman SA, Rapoport RM, Murad F. Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 1984 Dec 10; 259 (23): 14332-4
58. Winquist RJ, Faison EP, Waldman SA, et al. Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. Proc Natl Acad Sci U S A 1984 Dec; 81 (23): 7661-4
59. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002 Mar 27; 287 (12): 1531-40
60. Keating GM, Goa KL. Nesiritide: a review of its use in acute decompensated heart failure. Drugs 2003; 63 (1): 47-70
61. Cheng JW. Nesiritide: review of clinical pharmacology and role in heart failure management. Heart Dis 2002 May-Jun; 4 (3): 199-203
62. Hill JA, Hsu K, Pauly DF, et al. Sustained use of nesiritide to aid in bridging to heart transplant. Clin Cardiol 2003 May; 26 (5): 211-4
63. Moazami N, Damiano RJ, Bailey MS, et al. Nesiritide (BNP) in the management of postoperative cardiac patients. Ann Thorac Surg 2003 Jun; 75 (6): 1974-6
64. Sinha P, Chen JM, Flannery M, et al. Infections during left ventricular assist device support do not affect posttransplant outcomes. Circulation 2000 Nov 7; 102 (19 Suppl. 3): III194-9
65. Myers TJ, Khan T, Frazier OH. Infectious complications associated with ventricular assist systems. ASAIO J 2000 Nov-Dec; 46 (6): S28-36
66. Robbins RC, Kown MH, Portner PM, et al. The totally implantable novacor left ventricular assist system. Ann Thorac Surg 2001 Mar; 71 (3 Suppl.): S162-5
67. Didisheim P, Rose EA, Long JW, et al. Infection with clinical ventricular assist devices: clinical therapy. ASAIO J 2001 May-Jun; 47 (3): 195-6
68. Malani PN, Dyke DB, Pagani FD, et al. Nosocomial infections in left ventricular assist device recipients. Clin Infect Dis 2002 May 15; 34(10): 1295-300
69. Holman WL, Rayburn BK, McGiffin DC, et al. Infection in ventricular assist devices: prevention and treatment. Ann Thorac Surg 2003 Jun; 75 (6 Suppl.): S48-57
70. Goldstein DJ. Worldwide experience with the MicroMed DeBakey Ventricular Assist Device as a bridge to transplantation. Circulation 2003 Sep 9; 108 Suppl. 1: II272-7
71. Itescu S, Ankersmit JH, Kocher AA, et al. Immunobiology of left ventricular assist devices. Prog Cardiovasc Dis 2000 Jul-Aug; 43 (1): 67-80
72. Itescu S, John R. Interactions between the recipient immune system and the left ventricular assist device surface: immunological and clinical implications. Ann Thorac Surg 2003 Jun; 75 (6 Suppl.): S58-65
73. Itescu S, Schuster M, Burke E, et al. Immunobiologic consequences of assist devices. Cardiol Clin 2003 Feb; 21 (1): 119-33
74. Ankersmit HJ, Wieselthaler G, Moser B, et al. Transitory immunologic response after implantation of the DeBakey VAD continuous-axial-flow pump. J Thorac Cardiovasc Surg 2002 Mar; 123 (3): 557-61
75. Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis 2003 Oct 1; 37 (7): 933-8
76. Sivaratnam K, Duggan JM. Left ventricular assist device infections: three case reports and a review of the literature. ASAIO J 2002 Jan-Feb; 48(1): 2-7
77. Nurozler F, Argenziano M, Oz MC, et al. Fungal left ventricular assist device endocarditis. Ann Thorac Surg 2001 Feb; 71 (2): 614-8
78. Goldstein DJ, el-Amir NG, Ashton Jr RC, et al. Fungal infections in left ventricular assist device recipients: incidence, prophylaxis, and treatment. ASAIO J 1995 Oct-Dec; 41 (4): 873-5
79. Skinner JL, Harris C, Aaron MF, et al. Cost-benefit analysis of extended antifungal prophylaxis in ventricular assist devices. ASAIO J 2000 Sep-Oct; 46 (5): 587-9
80. Yu VL, Goetz A, Wagener M, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. N Engl J Med 1986; 315: 91-6
81. Loeffler AM. Uses of rifampin for infections other than tuberculosis. Pediatr Infect Dis J 1999 Jul; 18 (7): 631-2
82. Vesely JJ, Pien FD, Pien BC. Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy 1998 Mar-Apr; 18 (2): 345-57
83. Raad II, Hachem RY, Abi-Said D, et al. A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2. Cancer 1998 Jan 15; 82 (2): 403-11
84. Minev PA, El-Banayosy A, Minami K, et al. Differential indication for mechanical circulatory support following heart transplantation. Intensive Care Med 2001 Aug; 27 (8): 1321-7
85. Frazier OH, Rose EA, Oz MC, et al. Left ventricular assist system: multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 2001 Dec; 122 (6): 1186-95
86. Meyns B, Sergeant P, Herijgers P, et al. Bridging procedures to heart transplantation. World J Surg 2002 Feb; 26 (2): 212-7
87. Goldstein DJ, Beauford RB. Left ventricular assist devices and bleeding: adding insult to injury. Ann Thorac Surg 2003 Jun; 75 (6 Suppl.): S42-7
88. Vitali E, Lanfranconi M, Bruschi G, et al. Left ventricular assist devices as bridge to heart transplantation: the Niguarda experience. J Card Surg 2003 Mar-Apr; 18 (2): 107-13
89. Himmelreich G, Ullmann H, Riess H, et al. Pathophysiologic role of contact activation in bleeding followed by thromboembolic complications after implantation of a ventricular assist device. ASAIO J 1995 Jul-Sep; 41 (3): M790-4
90. McGee MG, Parnis SM, Nakatani T, et al. Extended clinical support with an implantable left ventricular assist device. ASAIO Trans 1989 Jul-Sep; 35 (3): 614-6
91. Rose EA, Levin HR, Oz MC, et al. Artificial circulatory support with textured interior surfaces: a counterintuitive approach to minimizing thromboembolism. Circulation 1994 Nov; 90 (5 Pt 2): II87-91
92. Spanier T, Oz M, Levin H, et al. Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiovasc Surg 1996 Oct; 112 (4): 1090-7
93. Brozena SC, Twomey C, Siegel J, et al. Heart transplantation in patients with heparin-induced thrombocytopenia on the Novacor left ventricular assist system. J Heart Lung Transplant 1998 Jul; 17 (7): 729-31
94. Christiansen S, Jahn UR, Meyer J, et al. Anticoagulative management of patients requiring left ventricular assist device implantation and suffering from heparin-induced thrombocytopenia type II. Ann Thorac Surg 2000 Mar; 69 (3): 774-7
95. Tandler R, Weyand M, Schmid C, et al. Long-term anticoagulation with recombinant hirudin in a patient on left ventricular assist device support. ASAIO J 2000 Nov-Dec; 46 (6): 792-4
96. Christiansen S, Jahn UR, Meyer J, et al. Successful cardiac transplantation after Novacor implantation in a HIT H-patient using heparin. J Cardiovasc Surg 2001 Dec; 42 (6): 769-71
97. Robitaille D, Carrier M, Cartier R, et al. Successful management strategy for mechanical assistance and heart transplantation in patients suffering from heparin-induced thrombocytopenia type II. J Heart Lung Transplant 2001 Nov; 20 (11): 1237-40
98. Mauron T, Lammle B, Wuillemin WA. Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins. Thromb Haemost 1998 Jul; 80 (1): 82-6
99. Tandler R, Weyand M, Schmid C, et al. Long-term anticoagulation with recombinant hirudin in a patient on left ventricular assist device support. ASAIO J 2000 Nov-Dec; 46 (6): 792-4
100. Wagner WR, Johnson PC, Heil BV, et al. Thrombin activity resides on LVAD Dacron inflow and outflow grafts. ASAIO J 1992 Jul-Sep; 38 (3): M634-7
101. Schmid C, Wilhelm M, Rothenburger M, et al. Effect of high dose platelet inhibitor treatment on thromboembolism in Novacor patients. Eur J Cardiothorac Surg 2000 Mar; 17 (3): 331-5
102. McGee MG, Myers TJ, Abou-Awdi N, et al. Extended support with a left ventricular assist device as a bridge to heart transplantation. ASAIO Trans 1991 Jul-Sep; 37 (3): M425-6
103. McCarthy PM, James KB, Savage RM, et al. Implantable left ventricular assist device: approaching an alternative for end-stage heart failure. Implantable LVAD Study Group. Circulation 1994 Nov; 90 (5 Pt 2): II83-6
104. Wang IW, Kottke-Marchant K, Vargo RL, et al. Hemostatic profiles of HeartMate ventricular assist device recipients. ASAIO J 1995 Jul-Sep; 41 (3): M782-7
105. RxList. Clinical pharmacology [online]. Available from URL: http://www.rxlist.com/cgi/generic/warfarin_cp.htm [Accessed 2003 Nov 2]
106. Swartz MT, Lowdermilk GA, Moroney DA, et al. Ventricular assist device support in patients with mechanical heart valves. Ann Thorac Surg 1999 Dec; 68 (6): 2248-51
107. Rao V, Slater JP, Edwards NM, et al. Surgical management of valvular disease in patients requiring left ventricular assist device support. Ann Thorac Surg 2001 May; 71 (5): 1448-53
108. Szukalski EA, Reedy JE, Pennington DG, et al. Oral anticoagulation in patients with ventricular assist devices. ASAIO Trans 1990 Jul-Sep; 36 (3): M700-3
109. Sapirstein JS, Pae Jr WE, Aufiero TX, et al. Long-term left ventricular assist device use before transplantation. ASAIO J 1995 Jul-Sep; 41 (3): M530-4
110. Slater JP, Rose EA, Levin HR, et al. Low thromboembolic risk without anticoagulation using advanced-design left ventricular assist devices. Ann Thorac Surg 1996 Nov; 62 (5): 1321-7
111. Yang YT, McElligot MA. Multiple actions of β-adrenoceptor agonists on skeletal muscle and adipose tissue. Biochem J 1989; 261: 1-10
112. Kim YS, Sainz RD. Beta-adrenergic agonists and hypertrophy of skeletal muscles. Life Sci 1992; 50: 397-407
113. Williams PEV. The use of beta-agonists as a means of altering body composition in livestock species. Nutr Abstr Rev 1987; 57: 453-64
114. Maltin CA, Delday MI, Reeds PJ. The effect of a growth promoting drug, clenbuterol, on fibre frequency and area in hind limb muscles from young male rats. Biosci Rep 1986; 6: 293-9
115. Petrou M, Wynne DG, Boheler KR, et al. Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes. Circulation 1995 Nov 1; 92 (9 Suppl.): II483-9
116. Wong K, Boheler KR, Bishop J, et al. Clenbuterol induces cardiac hypertrophy with normal functional, morphological and molecular features. Cardiovasc Res 1998 Jan; 37 (1): 115-22
117. Soppa GK, Malik AH, Terracciano CM, et al. Chronic administration of clenbuterol affects ventricular myocyte size and calcium handling in rats [abstract]. American Heart Association Abstracts from Scientific Sessions; 2003 Nov 9-12; Orlando
118. Terracciano CM, Birks E, Hardy J, et al. Clinical recovery with successful LVAD explantation correlates with increased sarcoplasmic reticulum (SR) Ca content but not with regression of cellular hypertrophy [abstract]. American Heart Association Abstracts from Scientific Sessions; 2003 Nov 9-12; Orlando
119. Yacoub MH, Birks EJ, Tansley P, et al. Bridge to recovery: the Harefield approach. J Congest Heart Fail Circ Suppl 2001 Mar; 2 (1): 27-30
120. Hon JK, Yacoub MH. Bridge to recovery with the use of left ventricular assist device and clenbuterol. Ann Thorac Surg 2003 Jun; 75 (6 Suppl.): S36-41
121. Cosgrove III DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992 Dec; 54 (6): 1031-6
122. Liu B, Tengborn L, Larson G, et al. Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations. Ann Thorac Surg 1995 Jun; 59 (6): 1534-40
123. Misfeld M, Dubbert S, Eleftheriadis S, et al. Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations. Ann Thorac Surg 1998 Sep; 66 (3): 792-9
124. Stammers AH, Huffman S, Alonso A, et al. The antiinflammatory effects of aprotinin in patients undergoing cardiac surgery with cardiopulmonary bypass. J Extra Corpor Technol 1997; 29: 114-22
125. Helman DN, Oz MC. Developing a comprehensive mechanical support program. J Card Surg 2001 May-Jun; 16 (3); 203-8
126. Pae Jr WE, Aufiero TX, Weldner PW, et al. Aprotinin therapy for insertion of ventricular assist devices for staged heart transplantation. J Heart Lung Transplant 1994 Sep-Oct; 13 (5): 811-6
127. Goldstein DJ, Seldomridge JA, Chen JM, et al. Use of aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality. Ann Thorac Surg 1995 May; 59 (5): 1063-7
128. Milano CA, Patel VS, Smith PK, et al. Risk of anaphylaxis from aprotinin re-exposure during LVAD removal and heart transplantation. J Heart Lung Transplant 2002 Oct; 21 (10): 1127-30
129. Goldstein DJ, Oz MC, Smith CR, et al. Safety of repeat aprotinin administration for LVAD recipients undergoing cardiac transplantation. Ann Thorac Surg 1996 Feb; 61 (2): 692-5
130. RxList. Clinical pharmacology [online]. Available from URL: http://www.rxlist.com/cgi/generic3/phytonadione_cp.htm [Accessed 2003 Nov 5]
131. Kaplon RJ, Gillinov AM, Smedira NG, et al. Vitamin K reduces bleeding in left ventricular assist device recipients. J Heart Lung Transplant 1999 Apr; 18 (4): 346-50
132. Pollack SV. Wound healing: a review. Ill: nutritional factors affecting wound healing. J Dermatol Surg Oncol 1979; 5: 615-9
133. Levenson SM, Gruber CA, Rettura G, et al. Supplemental vitamin A prevents the acute radiation-induced defect in wound healing. Ann Surg 1984; 200: 494-512
134. Levenson SM, Demetriou AA. Metabolic factors. In: Cohen IK, Diegelmann RF, Lindblad WJ, editors. Wound healing biochemical and clinical aspects. Philadelphia (PA): WB Saunders Co., 1992
135. Goetzl EJ, Wasserman SI, Gigli I, et al. Enhancement of random migration and chemotactic response of human leukocytes by ascorbic acid. J Clin Invest 1974; 53: 813-8
136. Nicosia RF, Belser P, Bonanno E, et al. Regulation of angiogenesis in vitro by collagen metabolism. In Vitro Cell Dev Biol 1991; 27A: 961-6
137. Yoshikawa T, Yoshida N, Manabe H, et al. Alpha-tocopherol protects against expression of adhesion molecules on neutrophils and endothelial cells. Biofactors 1998; 7 (1-2): 15-9
138. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000 Apr 25; 101 (16): 1899-906
139. May JM, Qu ZC, Mendiratta S, et al. Protection and recycling of alpha-tocopherol in human erythrocytes by intracellular ascorbic acid. Arch Biochem Biophys 1998 Jan 15; 349 (2): 281-9
140. Meydani SN, Meydani M, Blumberg JB, et al. Assessment of the safety of supplementation with different amounts of vitamin E in healthy older adults. Am J Clin Nutr 1998; 68: 311-8
141. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes: vitamin C, vitamin E, selenium, and carotenoids. Washington, DC: National Academy Press, 2000
142. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. 'Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico'. Lancet 1999 Aug 7; 354 (9177): 447-55
143. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20; 342 (3): 154-60